Recruiting × Anemia, Refractory, with Excess of Blasts × Clear all Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Phase 1/2 Recruiting
160 enrolled
UHKT-PTC-TMI-1
Phase 1/2 Recruiting
16 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
Phase NA Recruiting
30 enrolled
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
Phase 1 Recruiting
42 enrolled
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 Recruiting
70 enrolled
WATCH Tranfuse
Recruiting
80 enrolled
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Phase 2/3 Recruiting
316 enrolled
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
270 enrolled
ACCELERATE
Phase 2 Recruiting
358 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 Recruiting
63 enrolled
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Phase 1 Recruiting
100 enrolled
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Phase 1 Recruiting
130 enrolled
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 Recruiting
45 enrolled
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
Phase NA Recruiting
36 enrolled
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Recruiting
124 enrolled
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Phase 1/2 Recruiting
75 enrolled
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Phase 1/2 Recruiting
49 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1/2 Recruiting
30 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 Recruiting
30 enrolled
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Phase NA Recruiting
40 enrolled
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 Recruiting
42 enrolled
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
Phase NA Recruiting
157 enrolled
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Phase 2 Recruiting
40 enrolled
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Recruiting
50 enrolled